> > >>>2010122012>>

DSA
20101229 16:
48:
45Wednesday

I
gA

310015

DSA

.
.
.

,
30
DSADSA
1830
7(
23.
3%)
12(
40.
0%)

[
]
[
e]

30

11(
36.
7%)

(
P>0.
05)
(
3
)
9(
30.
0%)
(
33)
21
(
70.
0%)
(
P<0.
05)
8(
26.
7%)

22(
73.
3%)
,
(
P<0.
05)

DSA

DSA

[
]
[
]

Abst
r
actObj
ec
t
i
ve:
Toanal
yz
et
hedi
gi
t
al
subst
r
act
i
on

angi
ogr
aphy(
DSA)i
magi
ngf
eat
ur
esf
orhepat
i
cmet
ast
as
esf
r
om
r
ect
alcancerandi
dent
i
f
ychar
ac
t
er
i
s
t
i
c
soft
hebl
oods
uppl
yof

hepat
i
cmet
as
t
as
est
ogui
dei
nt
er
vent
i
onalt
her
apy.
Met
hods:
Thi
r
t
ycas
eswi
t
hhepat
i
cmet
ast
as
eswer
e
ex
ami
nedwi
t
hDSAbef
or
ei
nt
er
vent
i
onalt
her
apyt
oanal
yz
et
hel
oc
at
i
on,
number
s,
andbl
oods
uppl
yof
met
as
t
ases
.
Ot
her18c
aseswi
t
hpr
i
mar
yhepat
i
ccar
ci
nomass
er
v
edascont
r
ol
s.
Resul
t
s:
I
n30cases,
met
as
t
asesi
nt
hel
ef
thepat
i
cl
obewer
ei
n7cases(
23.
33%)
,i
nt
her
i
ghthepat
i
cl
obei
n12(
40%)
,
andi
nt
he
l
ef
tandr
i
ghthepat
i
cl
obei
n11(
36.
67%)
,
wi
t
hnosi
gni
f
i
cantdi
f
f
er
enc
ei
nt
hedi
s
t
r
i
but
i
onr
at
eofmet
as
t
ases
(
P>0.
05)
.
Met
as
t
as
eswer
ehy
po nodul
esi
n9cases(
30%)compar
edwi
t
ht
hatwer
emut
inodul
esi
n21
(
70%,
P<0.
05)
.
Met
as
t
as
eswi
t
hr
i
chbl
oodsuppl
ywer
ei
n8cas
es(
26.
67%)compar
edwi
t
ht
hatwi
t
hi
ns
uf
f
i
c
i
ent
bl
oodsuppl
yi
n22(
73.
33%,
P<0.
05)
.
Concl
usi
on:
Themaj
or
i
t
yofhepat
i
cmet
ast
asesf
r
om r
ec
t
alc
ancerwer
e
mul
t
i
pl
emet
as
t
aseswi
t
hi
nsuf
f
i
ci
entsuppl
ybl
ood.
DSAcanbepr
of
i
tt
oi
dent
i
f
yhepat
i
cmet
as
t
asesandpr
i
mar
y
hepat
i
ccar
ci
noma,
andpr
ovi
di
mpor
t
antevi
dencesf
ori
nt
er
vent
i
onal
t
her
apy
.
Keywor
dshepat
i
cmet
ast
asesf
r
om r
ect
alcancerpr
i
mar
yhepat
i
ccar
ci
nomadi
gi
t
als
ubs
t
r
act
i
on
angi
ogr
aphy(
DSA)di
f
f
er
ent
i
aldi
agnosi
s

10%20%[
1]

DSADSA
DSA
1
1.
1
20041200912DSA301812
287553.
415(
8
7)
112111812
6307854.
0
journal.9m ed.net/htm l/qikan/zxyjh/zjzxyjhzz/2010122012/lz/20101230091312460_554730.htm l

1/3

1.
2
Sel
di
nger
4 5FRHYas
hi
r
oDSA
3ml
/
s915ml

GE I
300CDCI

AGFA
1.
3

2P<0.
05
2
2.
1
7(
23.
3%)
12(
40.
0%)
11(
36.
7%)

(
P>0.
05)
7(
38.
9%)
6
(
33.
3%)
5(
27.
8%)
(
P>0.
05)

(
3)
9
(
30.
0%)
(
33)
21(
70.
0%)
14(
77.
8%)

4(
22.
2%)
(
2=4.
80,
P<0.
05)

(
2=5.
556,
P<0.
05)
11

2.
2
DSA:

,
,
,

:
,
,
,

308(
26.
7%)
22
(
73.
3%)
(
2=6.
533,
P<0.
05)
1814(
72.
2%)
4
(
27.
8%)
,
(

2=5.
556,
P<0.
05)
,
13
2.
3
3015411;
38;

11
3
3.
1

12.

Shi
r
ai
[
2]
85195,

,
2/
3,
1/
3,

3,

,
,
,

(
P>0.
05)

[
34]

3.
2
DSA,

(
P<0.
05)

(
P<0.
05)
,

1
3.
3
Fol
ey
[
5]
80%
[
6]

30
journal.9m ed.net/htm l/qikan/zxyjh/zjzxyjhzz/2010122012/lz/20101230091312460_554730.htm l

2/3

3.
4DSA
DSA

DSA

\
[
1\
]Pent
ec
ostMJ
.
Tr
anscat
het
ert
r
eat
mentofhepat
i
cmet
ast
ases(
Revi
ew)
\
[
J
\
]
.
AJ
R,
1993,
160(
5)
:
1171 1175.
\
[
2\
]Shi
r
aiY,
Wak
ai
T,
Oht
aniT,
etal
.
Col
or
ect
alcar
ci
nomamet
as
t
asest
ot
hel
i
v
er
:
Doespr
i
mar
yt
umor
l
oc
at
i
onaf
f
ec
ti
t
sl
obardi
st
r
i
but
i
on?\
[
J
\
]
.
Cancer
,
1996,
77(
11)
:
2213 2216.
\
[
3\
]Tonami
N,
Nakaj
i
maK,
YokoyamaK,
etal
.
Var
i
abl
epor
t
alci
r
c
ul
at
i
onf
r
om i
nf
er
i
ormesent
er
i
cv
ei
n
as
ses
s
edbyper r
ec
t
al
r
adi
onucl
i
deadmi
ni
st
r
at
i
on\
[
J
\
]
.
NulMedCommun,
1995,
16(
2)
:
92 98.
\
[
4\
].
\
[
J
\
]
.
2006,
11(
1)

46 47.
\
[
5\
]Fol
eyEF,
Kol
ec
k
iRV,
Schi
r
merBD.
Theaccur
acyofl
apar
os
c
opi
cul
t
r
as
oundi
nt
hedet
ect
i
onof
c
ol
or
ect
al
c
ancerl
i
vermat
ast
ases\
[
J
\
]
.
Am JSur
g,
1998,
176(
3)
:
262 291.
\
[
6\
].
23\
[
J
\
]
.
,
2010,
39(
3)
:
256 257.

Emai
l

journal.9m ed.net/htm l/qikan/zxyjh/zjzxyjhzz/2010122012/lz/20101230091312460_554730.htm l

3/3